SEATTLE, March 28 /CNW/ -- VentriPoint(TM) Diagnostics Ltd. (TSX: VPT)
today announced the board committee memberships and chair responsibilities of
its newly elected directors, Joseph Ashley, Treuman Katz, Eldon Smith, M.D.,
Udo Henseler, Ph.D., and Danny Dalla-Longa.
VentriPoint's Audit committee will be chaired by Henseler and comprised
of Katz and Dalla-Longa. The Compensation, Nominating and Corporate
Governance Committee will be chaired by Dalla-Longa and comprised of Katz,
Smith and Henseler. Ashley will serve as chairman of the board. Each
director has experience in biotechnology and/or with start-up companies, and
will hold office until the next annual meeting of shareholders.
"Our board members have developed and launched 18 medical diagnostic
products between them and have relationships at nearly all of our targeted
customer sites," said Edward Garth, VentriPoint CFO. "We are excited to apply
this exceptional experience to the development of our diagnostic tools, which
integrate with existing medical imaging systems to deliver rapid, accurate and
inexpensive heart measurements that are critical but unavailable. Having
worked with Joe in prior endeavors, I am excited to have the opportunity to
once again support him as he builds VentriPoint."
Ashley, chairman of the board, is president and CEO of VentriPoint
Diagnostics. He has successfully led the development of numerous companies in
the biomedical and diagnostics industries, including Beckman Instruments Inc.,
which grew into a $450 million industry leader and was acquired by SmithKline.
Ashley is also chairman of the board for Copernicus Therapeutics and a member
of the board of directors for Geospeza Inc. and Sound Pharmaceuticals Inc.
Katz, member of the Audit Committee and the Compensation, Nominating and
Corporate Governance Committee, is currently the chair of the Washington State
Board of Health and the previous president and CEO of Children's Hospital and
Regional Medical Center in Seattle. In this role he led strategic planning
that resulted in the creation and establishment of Child Health Organization,
a national venture of 42 hospital organizations. He is also a trustee of
Bastyr University in Seattle, a board member of the American Heart Association
and an advisory committee member of the University of Washington School of
Smith, member of the Compensation, Nominating and Corporate Governance
Committee, is the recipient of the 2005 Canadian Medical Association Medal of
Service and has published more than 250 papers and book chapters. He was
instrumental in the establishment of the Libin Cardiovascular Institute of
Alberta for which he currently serves as its chair of the Strategic Advisory
Board. Smith is a retired clinician and has been the chair of the Canadian
Heart Health Strategy and Action Plan, an initiative of the Government of
Henseler, chairman of the Audit Committee and member of the Compensation,
Nominating and Corporate Governance Committee, is president of Management
Services International, providing CEO and CFO services, and was the chairman
and CEO of eGene Inc. through its acquisition. He is also currently a board
member for Spire Corporation and Tutogen Inc.
Dalla-Longa, chairman of the Compensation, Nominating and Corporate
Governance Committee and member of the Audit Committee and the sole returning
director, is a vice president, Corporate Finance and co-founder of i3 Capital
Partners, a Canadian merchant bank focused on the energy and technology
industries. Prior thereto Dalla-Longa was vice president, Corporate Finance
at Rampart Securities and previously a corporate finance executive in the
brokerage industry and a partner with the international accounting firm, KPMG.
About VentriPoint Diagnostics
VentriPoint is a clinical diagnostic company based in Seattle that
commenced operations in January 2005 with a view to commercializing innovative
and patented imaging technologies developed by the University of Washington
(the "Technology"). Applying this Technology, VentriPoint is attempting to
develop a breakthrough diagnostic tool for the rapid and cost effective
measurement of a heart's volume and ventricular ejection fraction (heart
function), which Technology, together with its associated online service, will
be extendable to a variety of heart related disease states.
For further information, please contact:
Edward Garth, Chief Financial Officer
VentriPoint Diagnostics Ltd.
Telephone: (206) 283-0221
Facsimile: (206) 283-2309
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
VentriPoint Media Contacts:
Russo Partners LLC
Tracey Milani or Ian Stone
For further information:
For further information: Tracey Milani,
email@example.com, or Ian Stone,
firstname.lastname@example.org, both of Russo Partners LLC for VentriPoint,
+1-619-814-3510; or Edward Garth, Chief Financial Officer, VentriPoint
Diagnostics Ltd., +1-206-283-0221, Facsimile, +1-206-283-2309